Efficacy of a specific polyclonal equine F(ab') sub( 2) against avian influenza (H5N1) in ferrets: synergy with oseltamivir

Current therapies against avian influenza (H5N1) provide limited clinical benefit. FBF-001 is a highly purified equine polyclonal immunoglobulin fragment against H5N1. Using a ferret model of severe acute H5N1 infection, we assessed FBF-001 when administered on the same day or 1 day after viral chal...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2016-01, Vol.8 (9), p.1021-1021
Main Authors: Herbreteau, Cecile H, Denizot, Melanie, Lowther, Suzanne, Riddell, Sarah, Frazer, Leah, Haining, Jessica, Arkinstall, Rachel, Payne, Jean, Harper, Jenni, Johnson, Dayna, Pasquier, Anais, Middleton, Deborah, Saluzzo, Jean-Francois
Format: Article
Language:English
Subjects:
Mustela
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Current therapies against avian influenza (H5N1) provide limited clinical benefit. FBF-001 is a highly purified equine polyclonal immunoglobulin fragment against H5N1. Using a ferret model of severe acute H5N1 infection, we assessed FBF-001 when administered on the same day or 1 day after viral challenge, in comparison with oseltamivir therapy. Untreated animals died 2-3 days after challenge. FBF-001 prevented most severe illness and reduced nasal viral load, with best efficacy when administered on the day of viral challenge. Oseltamivir and FBF-001 had synergistic impact on survival. FBF-001 prevented severe consequences of lethal H5N1 challenge in ferrets by controlling viral replication, an effect synergistic to oseltamivir. FBF-001 has recently been granted EMA orphan drug status.
ISSN:1750-743X